Magnetar Financial LLC Trims Position in LivaNova PLC (NASDAQ:LIVN)

Magnetar Financial LLC decreased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 22.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 564,197 shares of the company’s stock after selling 165,916 shares during the period. Magnetar Financial LLC owned 1.04% of LivaNova worth $26,128,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Central Pacific Bank Trust Division increased its position in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares during the last quarter. Captrust Financial Advisors acquired a new position in LivaNova during the third quarter worth approximately $217,000. Sanctuary Advisors LLC acquired a new position in LivaNova during the third quarter worth approximately $219,000. Vestcor Inc acquired a new position in LivaNova during the fourth quarter worth approximately $204,000. Finally, Edgestream Partners L.P. acquired a new position in LivaNova during the third quarter worth approximately $244,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Up 1.1 %

NASDAQ LIVN opened at $40.84 on Thursday. LivaNova PLC has a 12 month low of $36.85 and a 12 month high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 97.24 and a beta of 1.10. The company’s fifty day moving average price is $45.60 and its two-hundred day moving average price is $48.89.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research report on Monday. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Barclays dropped their price objective on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday, March 7th. Finally, Mizuho lowered their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.